Johan Liwing
Chief Executive Officer Elicera Therapeutics
Johan Liwing (born 1974) has more than 20 years’ experience in senior roles within the life sciences sector, having previously served as CEO of Lipigon Pharmaceuticals and XNK Therapeutics, as well as a long-standing career at Johnson & Johnson Innovative Medicine, where he held global commercial and senior leadership roles. He has a solid background in corporate leadership within the pharmaceutical and biotechnology sectors and brings with him experience of leading clinical-stage companies through critical development phases, partnership discussions and fundraising.
Johan also has Master of Science in Engineering Physics from the Royal Institute of Technology, 1999.
Seminars
Tuesday 9th February 2027
Translating an iTANK-Enhanced CAR-T into the Clinic to Expand Treatment Opportunities for Glioblastoma Patients
2:15 pm
- Exploring how the iTANK platform is designed to enhance anti-tumour immune responses and address the immunosuppressive tumour microenvironment
- Reviewing the clinical rationale and development strategy underpinning the advancement of ELC-401 into patient evaluation
- Presenting early clinical experience with iTANK-enhanced CAR-T therapy and its potential to address significant unmet need in glioblastoma
